Troy Rafferty Plays Key Role in $425 Million Nexium and Prilosec Litigation
Nexium and Prilosec Litigation
Troy Rafferty, a nationally recognized attorney and shareholder at Rafferty Domnick Cunningham & Yaffa, has once again demonstrated his leadership in high-stakes pharmaceutical litigation. Rafferty played a central role in helping secure a $425 million global settlement in the multidistrict litigation (MDL) involving Nexium, Prilosec, and other proton pump inhibitors (PPIs) linked to kidney damage.
The settlement resolves thousands of claims alleging that pharmaceutical companies failed to adequately warn patients and doctors about the serious risks of chronic kidney disease, acute interstitial nephritis, and renal failure associated with long-term PPI use.
Learn More: Troy Rafferty Plays Key Role in $425 Million Nexium and Prilosec Litigation
